Briacell Therap (NASDAQ:BCTX) Cut to “Strong Sell” at Wall Street Zen

Briacell Therap (NASDAQ:BCTX) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $320.00.

Briacell Therap Price Performance

Briacell Therap stock opened at $4.28 on Friday. Briacell Therap has a one year low of $3.60 and a one year high of $98.20. The business’s fifty day moving average is $4.13 and its 200 day moving average is $7.58. The stock has a market capitalization of $31.03 million, a PE ratio of -0.18 and a beta of 1.30.

Briacell Therap (NASDAQ:BCTX) last announced its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter. As a group, sell-side analysts expect that Briacell Therap will post -2.45 EPS for the current fiscal year.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is owned by institutional investors and hedge funds.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.